Rank #1384NRIX

Nurix Therapeutics, Inc.

$15.79

2.00% (Daily)

Market Cap

$1.62B

Revenue

$83.98M

Rank by MCap

#1384

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Arthur T. Sands M.D., Ph.D.

Headquarters

Brisbane, CA

Employees

317

About Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BT...